{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T01:45:04Z","timestamp":1789609504016,"version":"build-2803163510"},"reference-count":48,"publisher":"Cambridge University Press (CUP)","license":[{"start":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T00:00:00Z","timestamp":1775520000000},"content-version":"unspecified","delay-in-days":96,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["cambridge.org"],"crossmark-restriction":true},"short-container-title":["Epidemiol. Infect."],"published-print":{"date-parts":[[2026]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>In low-prevalence settings, the epidemiological yield of screening strategies for controlling vancomycin-resistant enterococci (VRE) outbreaks has not been fully established. We retrospectively analysed a prolonged VRE outbreak at a 536-bed tertiary-care hospital in Japan from 2010 to 2021 to evaluate sequential screening strategies across epidemic phases and to identify risk factors for VRE acquisition. Hospital-wide, admission-based, antimicrobial exposure-based, passive, and haemodialysis-targeted screening strategies were implemented over time. Screening yields were compared longitudinally, and a retrospective case\u2013control study was performed using data from the initial hospital-wide screening phase. Molecular epidemiology was assessed by pulsed-field gel electrophoresis (PFGE). In total, 169 VRE-positive patients were identified, including seven infections and 162 asymptomatic carriers. Hospital-wide screening in the early epidemic phase showed the highest positivity rate (0.91%), whereas targeted strategies consistently yielded lower rates (0.09\u20130.34%). Haemodialysis, specific oral care practices, and prior exposure to carbapenems, glycopeptides, and piperacillin\/tazobactam were independently associated with VRE acquisition. PFGE revealed substantial genetic diversity, suggesting sustained nosocomial transmission with repeated introductions. Early broad-based screening may be epidemiologically efficient in the initial phase of VRE outbreaks in low-prevalence settings, followed by adaptive refinement for long-term control.<\/jats:p>","DOI":"10.1017\/s0950268826101344","type":"journal-article","created":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T08:17:29Z","timestamp":1775549849000},"update-policy":"https:\/\/doi.org\/10.1017\/policypage","source":"Crossref","is-referenced-by-count":2,"title":["Dynamic screening strategies for the control of a prolonged vancomycin-resistant enterococci outbreak: A decade-long study in a Japanese tertiary hospital"],"prefix":"10.1017","volume":"154","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5926-2713","authenticated-orcid":false,"given":"Hiroyuki","family":"Shimizu","sequence":"first","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04dd5bw95","id-type":"ROR","asserted-by":"publisher"}],"name":"Fujisawa City Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoko","family":"Kawada","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04dd5bw95","id-type":"ROR","asserted-by":"publisher"}],"name":"Fujisawa City Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoyuki","family":"Osumi","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04dd5bw95","id-type":"ROR","asserted-by":"publisher"}],"name":"Fujisawa City Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masashi","family":"Sakai","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04dd5bw95","id-type":"ROR","asserted-by":"publisher"}],"name":"Fujisawa City Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noboru","family":"Yoshimoto","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04dd5bw95","id-type":"ROR","asserted-by":"publisher"}],"name":"Fujisawa City Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsuo","family":"Sato","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04dd5bw95","id-type":"ROR","asserted-by":"publisher"}],"name":"Fujisawa City Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masanori","family":"Nishikawa","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04dd5bw95","id-type":"ROR","asserted-by":"publisher"}],"name":"Fujisawa City Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"56","published-online":{"date-parts":[[2026,4,7]]},"reference":[{"key":"S0950268826101344_r42","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhin.2019.12.007"},{"key":"S0950268826101344_r43","doi-asserted-by":"publisher","DOI":"10.1017\/S0950268800030478"},{"key":"S0950268826101344_r13","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhin.2005.02.016"},{"key":"S0950268826101344_r1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(88)91037-9"},{"key":"S0950268826101344_r3","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(22)00811-8"},{"key":"S0950268826101344_r6","doi-asserted-by":"publisher","DOI":"10.1017\/ash.2022.365"},{"key":"S0950268826101344_r30","doi-asserted-by":"publisher","DOI":"10.1016\/j.idc.2016.07.009"},{"key":"S0950268826101344_r8","doi-asserted-by":"publisher","DOI":"10.1186\/s13756-019-0628-x"},{"key":"S0950268826101344_r18","doi-asserted-by":"publisher","DOI":"10.1128\/jcm.33.9.2233-2239.1995"},{"key":"S0950268826101344_r39","unstructured":"[39] Australian Commission on Safety and Quality in Health Care (2019) Core Strategies for VRE Prevention and Control. https:\/\/www.safetyandquality.gov.au\/sites\/default\/files\/2019-12\/core_strategies_for_vre_prevention_and_control_03_12_19.pdf (accessed 8 March 2026)."},{"key":"S0950268826101344_r24","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2013.01.004"},{"key":"S0950268826101344_r45","doi-asserted-by":"publisher","DOI":"10.3390\/microorganisms12010149"},{"key":"S0950268826101344_r46","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijmm.2025.151658"},{"key":"S0950268826101344_r48","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2025.1656334"},{"key":"S0950268826101344_r44","doi-asserted-by":"publisher","DOI":"10.1016\/j.scitotenv.2020.140804"},{"key":"S0950268826101344_r16","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dky075"},{"key":"S0950268826101344_r36","doi-asserted-by":"publisher","DOI":"10.9778\/cmajo.20170034"},{"key":"S0950268826101344_r40","unstructured":"[40] Swissnoso (2018) Temporary Expert Guidance for Healthcare Institutions to Contain the Spread of Vancomycin Resistant Enterococci (VRE) in Switzerland. https:\/\/www.swissnoso.ch\/fileadmin\/swissnoso\/Dokumente\/1_Swissnoso_allgemein\/180912_Temporary_expert_guidance_for_healthcare_institutions_to_contain_the_spread_of_VRE_final_1.0.pdf (accessed 8 March 2026)."},{"key":"S0950268826101344_r37","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.00686-14"},{"key":"S0950268826101344_r20","unstructured":"[20] Centers for Disease Control and Prevention (2024) Vancomycin-Resistant Enterococci (VRE) Basics. https:\/\/www.cdc.gov\/vre\/about\/index.html (accessed 14 January 2026)."},{"key":"S0950268826101344_r28","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200012283432604"},{"key":"S0950268826101344_r34","doi-asserted-by":"publisher","DOI":"10.1086\/338234"},{"key":"S0950268826101344_r22","unstructured":"[22] European Centre for Disease Prevention and Control (2023) Antimicrobial resistance surveillance in Europe 2023\u20132021 data. https:\/\/www.ecdc.europa.eu\/en\/publications-data\/antimicrobial-resistance-surveillance-europe-2023-2021-data (accessed 8 March 2026)."},{"key":"S0950268826101344_r10","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.00211-16"},{"key":"S0950268826101344_r25","unstructured":"[25] Ministry of Health, Labour and Welfare (2023) Japan Nosocomial Infections Surveillance. https:\/\/janis.mhlw.go.jp\/report\/kensa.html (accessed 14 January 2026)."},{"key":"S0950268826101344_r14","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajic.2007.10.007"},{"key":"S0950268826101344_r15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jgar.2022.05.019"},{"key":"S0950268826101344_r41","doi-asserted-by":"publisher","DOI":"10.1186\/s13756-016-0140-5"},{"key":"S0950268826101344_r33","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2014.05.016"},{"key":"S0950268826101344_r4","doi-asserted-by":"publisher","DOI":"10.1086\/430909"},{"key":"S0950268826101344_r21","unstructured":"[21] European Centre for Disease Prevention and Control (2025) Antimicrobial Resistance in the EU\/EEA (EARS-Net) - Annual Epidemiological Report for 2024. https:\/\/www.ecdc.europa.eu\/en\/publications-data\/antimicrobial-resistance-eueea-ears-net-annual-epidemiological-report-2024 (accessed 8 March 2026)."},{"key":"S0950268826101344_r12","first-page":"362","article-title":"SHEA guideline for preventing nosocomial transmission of multidrug-resistant strains of Staphylococcus aureus and enterococcus","volume":"24","author":"Muto","year":"2003","journal-title":"Infection Control and Hospital Epidemiology"},{"key":"S0950268826101344_r29","first-page":"36","article-title":"Resistant enterococci: A prospective study of prevalence, incidence, and factors associated with colonization in a university hospital","volume":"17","author":"Weinstein","year":"1996","journal-title":"Infection Control and Hospital Epidemiology"},{"key":"S0950268826101344_r2","first-page":"217","article-title":"Vancomycin-resistant enterococcal infections: Epidemiology, clinical manifestations, and optimal management","volume":"8","author":"O\u2019Driscoll","year":"2015","journal-title":"Infection and Drug Resistance"},{"key":"S0950268826101344_r26","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-135-3-200108070-00009"},{"key":"S0950268826101344_r32","first-page":"686","article-title":"Vancomycin-resistant Entrococci colonization in chronic hemodialysis patients and its risk factors in southern Iran (2005-2006)","volume":"14","author":"Shaghaghian","year":"2012","journal-title":"Iranian Red Crescent Medical Journal"},{"key":"S0950268826101344_r19","unstructured":"[19] Centers for Disease Control and Prevention (2024) Antimicrobial Resistance Threats in the United States, 2021\u20132022. https:\/\/www.cdc.gov\/antimicrobial-resistance\/media\/pdfs\/antimicrobial-resistance-threats-update-2022-508.pdf (accessed 14 January 2026)."},{"key":"S0950268826101344_r17","doi-asserted-by":"publisher","DOI":"10.1128\/jcm.33.1.24-27.1995"},{"key":"S0950268826101344_r47","doi-asserted-by":"publisher","DOI":"10.1016\/j.jgar.2022.07.008"},{"key":"S0950268826101344_r9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhin.2014.09.002"},{"key":"S0950268826101344_r31","doi-asserted-by":"publisher","DOI":"10.1186\/2047-2994-1-31"},{"key":"S0950268826101344_r5","doi-asserted-by":"publisher","DOI":"10.1017\/ice.2015.228"},{"key":"S0950268826101344_r38","unstructured":"[38] Department for Health and Wellbeing, South Australia (2020) Vancomycin-resistant Enterococci (VRE): Infection Prevention and Control Clinical Guidelines. https:\/\/www.sahealth.sa.gov.au\/wps\/wcm\/connect\/e7b306004023a72496fcbfd30eb2c8cd\/Clinical_Guideline_Vancomycin_Resistant_Enterococci_%28VRE%29_Infection_Prevention_and_Control_Clinical_Guideline_v6.3_%28May2020%29.pdf?MOD=AJPERES&CACHEID=ROOTWORKSPACE-e7b306004023a72496fcbfd30eb2c8cd-ps9F819 (accessed 8 March 2026)."},{"key":"S0950268826101344_r11","doi-asserted-by":"publisher","DOI":"10.1186\/s13756-021-00906-x"},{"key":"S0950268826101344_r7","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhin.2013.06.016"},{"key":"S0950268826101344_r35","doi-asserted-by":"publisher","DOI":"10.33321\/cdi.2003.27.30"},{"key":"S0950268826101344_r23","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2012.03.003"},{"key":"S0950268826101344_r27","doi-asserted-by":"publisher","DOI":"10.1186\/s13756-024-01498-y"}],"container-title":["Epidemiology and Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cambridge.org\/core\/services\/aop-cambridge-core\/content\/view\/S0950268826101344","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T06:58:50Z","timestamp":1784271530000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cambridge.org\/core\/product\/identifier\/S0950268826101344\/type\/journal_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":48,"alternative-id":["S0950268826101344"],"URL":"https:\/\/doi.org\/10.1017\/s0950268826101344","relation":{},"ISSN":["0950-2688","1469-4409"],"issn-type":[{"value":"0950-2688","type":"print"},{"value":"1469-4409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026]]},"assertion":[{"value":"\u00a9 The Author(s), 2026. Published by Cambridge University Press","name":"copyright","label":"Copyright","group":{"name":"copyright_and_licensing","label":"Copyright and Licensing"}},{"value":"This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http:\/\/creativecommons.org\/licenses\/by\/4.0), which permits unrestricted re-use, distribution and reproduction, provided the original article is properly cited.","name":"license","label":"License","group":{"name":"copyright_and_licensing","label":"Copyright and Licensing"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}],"article-number":"e50"}}